Gary D. Berman

Gary D. Berman

Allergy and Immunology
825 Nicollet Mall
Suite 1149
Minneapolis, MN 55402

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.

Journal: Human vaccines & immunotherapeutics
Published: January 21, 2025

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine.

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine.

Journal: The Journal of infectious diseases
Published: September 30, 2024

Long-term safety and tolerability of zavegepant 10-mg nasal spray with concomitant use of anti-calcitonin gene-related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open-label study.

Long-term safety and tolerability of zavegepant 10-mg nasal spray with concomitant use of anti-calcitonin gene-related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open-label study.

Journal: Headache
Published: August 20, 2024

A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.

A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.

Journal: Cephalalgia : an international journal of headache
Published: April 25, 2024

Safety and durability of mRNA-1273-induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial.

Safety and durability of mRNA-1273-induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial.

Journal: EClinicalMedicine
Published: January 26, 2024

Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States.

Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States.

Journal: Journal of pain research
Published: December 08, 2023

Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.

Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.

Journal: The journal of allergy and clinical immunology. In practice
Published: June 22, 2023

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.

Journal: The New England journal of medicine
Published: October 19, 2022

Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials.

Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: July 07, 2022

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.

Journal: The New England journal of medicine
Published: August 11, 2021

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.

Journal: Headache
Published: June 03, 2020

Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis.

Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: December 28, 2018
Showing 1-12 of 17

Last Updated: 09/26/2026